MX2016003419A - Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico. - Google Patents

Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.

Info

Publication number
MX2016003419A
MX2016003419A MX2016003419A MX2016003419A MX2016003419A MX 2016003419 A MX2016003419 A MX 2016003419A MX 2016003419 A MX2016003419 A MX 2016003419A MX 2016003419 A MX2016003419 A MX 2016003419A MX 2016003419 A MX2016003419 A MX 2016003419A
Authority
MX
Mexico
Prior art keywords
mers
compositions
methods
immunogenic
cov
Prior art date
Application number
MX2016003419A
Other languages
English (en)
Inventor
Smith Gale
Massare Michael
Liu Ye
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of MX2016003419A publication Critical patent/MX2016003419A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Abstract

Se describen en la presente nanopartículas que contienen proteínas del virus de MERS en estructuras de polímero, y composiciones que contienen las nanopartículas formuladas para la administración como composiciones imunogénicas. También se proporcionan en la presente constructos de vector que codifican las proteínas, y células hospederas que contienen los constructos del vector. La descripción también incluye métodos para hacer las nanopartículas y administrarlos a vertebrados, incluyendo métodos para inducir las respuestas inmunitarias para MERS que reducen o previenen la infección por el virus.
MX2016003419A 2013-09-19 2014-09-19 Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico. MX2016003419A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361880111P 2013-09-19 2013-09-19
PCT/US2014/056517 WO2015042373A1 (en) 2013-09-19 2014-09-19 Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods

Publications (1)

Publication Number Publication Date
MX2016003419A true MX2016003419A (es) 2016-10-10

Family

ID=51660661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003419A MX2016003419A (es) 2013-09-19 2014-09-19 Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.

Country Status (14)

Country Link
US (1) US10751410B2 (es)
EP (1) EP3046579A1 (es)
JP (1) JP6643239B2 (es)
KR (1) KR102399854B1 (es)
CN (1) CN105555306B (es)
BR (1) BR112016006122B1 (es)
CA (1) CA2922258C (es)
HK (1) HK1225631A1 (es)
IL (1) IL244298B (es)
MX (1) MX2016003419A (es)
RU (1) RU2685185C2 (es)
SA (1) SA516370772B1 (es)
SG (2) SG10201802194WA (es)
WO (1) WO2015042373A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10781426B2 (en) * 2012-09-23 2020-09-22 Erasmus University Medical Center Rotterdam Human Betacoronavirus lineage C and identification of N-terminal dipeptidyl peptidase as its virus receptor
US9889194B2 (en) 2013-03-01 2018-02-13 New York Blood Center, Inc. Immunogenic composition for MERS coronavirus infection
AU2014354797C1 (en) 2013-11-29 2018-02-01 Inovio Pharmaceuticals, Inc. MERS-CoV vaccine
US11103575B2 (en) 2014-02-28 2021-08-31 The New York Blood Center, Inc. Immunogenic composition for MERS coronavirus infection
JP2017006008A (ja) * 2015-06-17 2017-01-12 オーストリッチファーマ株式会社 Ｍｅｒｓ用抗体および抗血清
IL257800B2 (en) 2015-09-03 2023-11-01 Novavax Inc Immune compositions with improved stability and immunogenicity
CN106119213A (zh) * 2016-06-20 2016-11-16 中国疾病预防控制中心病毒病预防控制所 以流感病毒M1为骨架的MERS‑CoV嵌合型VLPs疫苗
EP3541419B1 (en) * 2016-11-18 2022-01-05 New York Blood Center, Inc. Immunogenic composition for mers coronavirus infection
WO2018097603A2 (ko) * 2016-11-23 2018-05-31 에스케이케미칼 주식회사 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
KR102167727B1 (ko) * 2017-06-21 2020-10-20 경희대학교 산학협력단 드로소필라 멜라노개스터 s2를 이용한 메르스 항원 단백질 생산방법
KR101895228B1 (ko) * 2017-08-23 2018-10-30 대한민국 중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도
IL305911A (en) 2018-03-19 2023-11-01 Novavax Inc Multifunctional nanoparticle vaccines for influenza
IL295142A (en) * 2020-01-27 2022-09-01 Novavax Inc Formulations for the vaccine against the corona virus
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US11202753B1 (en) 2020-03-06 2021-12-21 Aquavit Pharmaceuticals, Inc. Systems and methods for generating immune responses in subjects using microchannel delivery devices
CN111484560A (zh) * 2020-03-24 2020-08-04 深圳市华启生物科技有限公司 冠状病毒模型及其应用
CN111450047A (zh) * 2020-03-25 2020-07-28 天津大学 一种mers病毒免疫凝胶制剂的合成方法
CN115867662A (zh) * 2020-04-22 2023-03-28 浦项工科大学校产学协力团 形成三聚体的新型冠状病毒肺炎(covid-19)重组刺突蛋白、在植物中大量产生重组刺突蛋白的方法和基于其制备疫苗组合物的方法
US11129890B1 (en) * 2020-05-19 2021-09-28 Vigene Biosciences, Inc. Non-integrating HIV-1 comprising mutant RT/IN proteins and the SARS-CoV-2 spike protein
CN113943373B (zh) * 2020-10-27 2022-09-06 中国科学院微生物研究所 一种β冠状病毒多聚体抗原、其制备方法和应用
WO2022115503A1 (en) * 2020-11-25 2022-06-02 Dupont Nutrition Biosciences Aps Treatment and prevention of coronavirus infection
CN114057894B (zh) * 2021-06-18 2022-08-05 国药中生生物技术研究院有限公司 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1544007A (en) 1921-08-11 1925-06-30 Hughes Arthur Sheridan Toilet partition
US4520019A (en) 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4505899A (en) 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4435386A (en) 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4505900A (en) 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
AU2003213060A1 (en) 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
WO2004085633A1 (en) * 2003-03-24 2004-10-07 The University Of Hong Kong A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
CN1237184C (zh) 2003-06-03 2006-01-18 中国科学院上海药物研究所 抗SARS－CoV药物作用靶标、药物筛选方法及抗SARS药物
EP2231704B1 (en) * 2007-12-17 2015-08-12 Medical Research Council Technology Hepatitis c virus antibodies
MX2011006205A (es) 2008-12-09 2011-09-01 Novavax Inc Proteinas f del vrs modificadas y metodos de uso de las mismas.
WO2011005183A1 (en) 2009-07-10 2011-01-13 Isconova Ab New composition
RU2403063C1 (ru) * 2009-08-28 2010-11-10 Автономная некоммерческая организация "Научно-исследовательский институт диагностики и профилактики болезней человека и животных" (АНО "НИИ ДПБ") Вакцина инактивированная комбинированная против вирусной диареи, рота-, коронавирусной болезней и эшерихиоза крупного рогатого скота

Also Published As

Publication number Publication date
CA2922258C (en) 2022-11-29
SG10201802194WA (en) 2018-05-30
EP3046579A1 (en) 2016-07-27
IL244298A0 (en) 2016-04-21
IL244298B (en) 2021-06-30
HK1225631A1 (zh) 2017-09-15
KR102399854B1 (ko) 2022-05-19
RU2016111934A3 (es) 2018-03-22
JP2016536346A (ja) 2016-11-24
RU2685185C2 (ru) 2019-04-16
KR20160055164A (ko) 2016-05-17
SA516370772B1 (ar) 2023-01-08
JP6643239B2 (ja) 2020-02-12
RU2016111934A (ru) 2017-10-05
CN105555306A (zh) 2016-05-04
SG11201601423SA (en) 2016-04-28
CN105555306B (zh) 2019-12-03
US20160206729A1 (en) 2016-07-21
BR112016006122B1 (pt) 2023-11-14
WO2015042373A1 (en) 2015-03-26
US10751410B2 (en) 2020-08-25
CA2922258A1 (en) 2015-03-26
BR112016006122A2 (pt) 2017-09-26

Similar Documents

Publication Publication Date Title
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
MX2018007627A (es) Vacuna contra el virus del zika.
MX2019004913A (es) Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
MD3718565T2 (ro) Vaccinuri împotriva virusului respirator
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
EA201290876A1 (ru) Композиции индуцированных дендритных клеток и их использование
EA201792407A2 (ru) Композиции, содержащие буфер, составы вакцин, которые содержат композиции, содержащие буфер, и пути их применения
EA201391183A1 (ru) Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2017002803A (es) Coronavirus bovino atenuado y vacunas relacionadas.
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
MX2015003765A (es) Arterivirus.
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
MX366051B (es) Composiciones del virus del síndrome reproductor y respiratorio de porcino y sus usos.
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
PH12015500095B1 (en) Attenuated swine influenza vaccines and methods of making and use thereof
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
MX350236B (es) Composiciones de peptidos para el tratamiento y diagnostico de la fiebre por virus del dengue.
MX2015011064A (es) Vacuna contra el virus de la leucemia bovina.